Geroscience Basics
What Is Geroscience?
Geroscience studies aging itself as the root risk for chronic disease. Animal results are strong; human evidence is early, and no aging drug is approved.
You may have seen the word attached to a new lab, a startup’s pitch deck or a headline about a pill that treats aging. If you’re wondering what geroscience is, and whether it has anything to offer people trying to live longer and better, the definition is simpler than the marketing around it. Humanic Blue starts with that definition before looking at the experiments behind the promise.
Geroscience is the field that studies the biology of aging as the common root of chronic disease. Instead of treating heart disease, cancer, diabetes and dementia one at a time, it asks whether slowing the underlying aging processes could delay many of them at once. That idea is called the geroscience hypothesis. In animals, it has solid support: dietary restriction, genetic changes and some drugs, such as rapamycin, extend lifespan in mice. In humans, the evidence is early. One randomized trial of calorie restriction slightly slowed a blood-based measure of aging. No drug is approved to treat aging, and the flagship human trial, TAME, is still raising money to launch.
Key Takeaways
- Geroscience studies whether targeting aging processes could delay several chronic diseases and extend healthspan—the years lived in good health.
- Interventions that target aging processes extend lifespan in laboratory animals, including mice. These results do not establish the same effects in people.
- No intervention has been shown to slow human aging in a way that delays multiple diseases or extends lifespan, and no drug has an FDA-approved aging indication.
The idea in one sentence
Think of chronic diseases as leaks in an old house’s plumbing. Medicine usually patches each leak as it appears. Geroscience asks whether the pipes themselves can be kept from corroding so fast.
The field’s founding statement came in a 2014 commentary in Cell by biologist Brian Kennedy and colleagues from institutions including the Buck Institute for Research on Aging, Stanford University and the National Institute on Aging. They wrote that genetic, dietary and drug approaches can delay aging in mammals, that aging is the greatest risk factor for most of the chronic diseases behind both illness and death, and that it’s critical to expand geroscience research aimed at extending human healthspan.
Healthspan, the years lived in good health, is the stated target. A longer lifespan may follow, but it isn’t the primary promise.
What is the geroscience hypothesis?
The testable version of the idea has a name. A team led by Columbia and Duke researchers, writing in Nature Aging in 2023, summarized it: “therapy to slow or reverse molecular changes that occur with aging can delay or prevent multiple chronic diseases and extend healthy lifespan.”
In plain terms: if the hypothesis is right, one intervention could lower the risk of many diseases at once. If it’s wrong, aging research will still produce useful biology, but not a shortcut around disease-by-disease medicine.
Which human outcomes would test the hypothesis beyond a change in an aging marker?
The hallmarks: what “aging” means at the cell level
To target aging, you need to define it. A widely cited framework is known as the hallmarks of aging, updated in 2023 in Cell by Carlos López-Otín of the University of Oviedo and colleagues. They proposed 12:
| Hallmark | In plain English |
|---|---|
| Genomic instability | DNA damage accumulates |
| Telomere attrition | Chromosome end-caps shorten |
| Epigenetic alterations | Gene on/off switches drift |
| Loss of proteostasis | Protein quality control falters |
| Disabled macroautophagy | Cellular recycling slows |
| Deregulated nutrient-sensing | Growth and fuel signals misfire |
| Mitochondrial dysfunction | Cellular power plants decline |
| Cellular senescence | Damaged cells stop dividing but linger |
| Stem cell exhaustion | Repair reserves run down |
| Altered intercellular communication | Signals between cells go awry |
| Chronic inflammation | Low-grade inflammation persists |
| Dysbiosis | Gut microbial communities shift |
For a feature to count, the authors required three things: it appears with age, speeding it up accelerates aging, and slowing it decelerates aging. That third test has mostly been met in animals, not people.
Two of the five authors report commercial interests in the field, according to the paper’s declarations. Maria Blasco is a founder and shareholder of Life Length, which sells telomere-length tests. Manuel Serrano is a shareholder and advisor of Altos Labs and Rejuveron Senescence Therapeutics.
What do the animal and human studies show?
In animals: strong. The National Institute on Aging’s Interventions Testing Program tests compounds in genetically diverse mice. Its most famous result appeared in Nature in 2009: “Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.” Rapamycin is an immune-suppressing drug used in transplant medicine. None of the animal lifespan results has been shown in people.
In humans: early. One of the few randomized human tests is a secondary analysis of CALERIE, a randomized trial in which adults without obesity were assigned to 25% calorie restriction or their usual diet for two years. Restriction slightly slowed DunedinPACE, an estimate of aging pace based on chemical patterns on DNA. These patterns, called DNA methylation, are used to build aging estimates known as epigenetic clocks. Other clocks, including PhenoAge and GrimAge, did not change significantly. A change in a clock score does not establish that people developed fewer diseases or lived longer. The authors wrote that “Treatment effect sizes were small” and that “a conclusive test of the geroscience hypothesis will require trials with long-term follow-up.” Two authors, including Daniel Belsky, are inventors of DunedinPACE, which has been licensed to a commercial entity.
The flagship trial: not yet running. TAME, short for Targeting Aging with Metformin, was proposed in 2016 by Nir Barzilai of Albert Einstein College of Medicine and colleagues. It would test whether metformin, a diabetes drug used for decades, delays the onset of several age-related diseases together.
The American Federation for Aging Research, which leads the effort, describes the proposed project as a six-year, 14-site trial enrolling more than 3,000 people aged 65 to 79. Rechecked on September 29, 2026, the sponsor page still said AFAR was raising money to launch it. We found no TAME-specific registration in ClinicalTrials.gov, so the design remains a proposal, not an enrolling trial.
AFAR says it hopes a successful trial could support FDA approval for a drug to treat aging—an approved use called an indication. That is the sponsor’s regulatory ambition, not a current FDA position or an approval.
What evidence is still needed to connect animal lifespan findings with human aging outcomes?
What isn’t geroscience?
Geroscience is a research field. It isn’t a clinic menu.
Clinics and supplement brands now use the language of the hallmarks to sell products that haven’t been tested for any aging outcome in people. Our reviews of two popular examples found the same gap. Senolytics, drugs designed to clear senescent cells, have improved health and lifespan in mice but haven’t been shown to slow aging in humans (What Are Senolytics, and Do They Work?). Stem-cell therapy hasn’t been shown to turn back human aging and remains investigational (Can Stem Cell Therapy Reverse Aging?).
A useful test for any “geroscience” product: which human trial, of what size, measured which health outcome?
What’s Interesting
TAME would test both a drug and a way of measuring its effects: whether metformin can delay a group of age-related diseases, rather than just one disease. AFAR hopes that a successful result could help establish a route to regulatory approval for treatments targeting aging. That remains the sponsor’s goal, not an agreed FDA pathway.
Metformin is a generic drug, and TAME’s backers describe that as a funding difficulty. Barzilai told NPR in 2024: “The main obstacle with funding this study is that metformin is a generic drug, so no pharmaceutical company is standing to make money.” The same report said the National Institute on Aging had set aside about $5 million toward a study estimated to cost $45 million to $70 million. That’s a detail worth remembering the next time a product claims to have already solved aging.
What This Means in Practice
- A research field. “Geroscience” describes a scientific program; the word alone does not establish that a treatment works.
- Different outcomes. A human trial measuring disease or survival answers a different question from a mouse lifespan experiment or a change in an aging-clock score.
- Regulatory status. No drug is FDA-approved for aging. Off-label use means prescribing an approved drug for a use outside its approval; it does not remove the drug’s risks.
- A separate evidence base. Research on blood-pressure and cholesterol management, physical activity, smoking and screening concerns human health outcomes; it does not validate drugs aimed at aging. That evidence is discussed in What Are the Best Habits for Longevity?
A clinician can explain the risks of any off-label drug. ClinicalTrials.gov lists registered aging trials for anyone interested in participating.
Two highly marketed edges of the field get their own evidence checks in Peptides for Longevity and Young Plasma and Plasma Exchange.
Bottom Line
Geroscience is the science of aging as a shared cause of chronic disease, built on the hypothesis that slowing aging processes could delay many diseases at once. Its animal evidence is strong, with rapamycin and other interventions extending mouse lifespan. Its human evidence is early: a small slowing of one aging measure with calorie restriction, and a flagship metformin trial that still needs funding to launch. No drug is approved to treat aging. For the question of living longer and better, the missing evidence is whether targeting aging processes reduces disease, disability or deaths in people; an improved clock score alone cannot answer it.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01What did this article make clearer about the gap between an aging mechanism and a proven human outcome?
- 02Which claim would you want to see tested in people before it affected a real health decision?
- 03What question should readers keep asking when "What Is Geroscience" shows up in longevity marketing?
Extra Insights & Sources
The evidence summaries and linked sources behind this article.
What We Know
- Aging is the largest risk factor for most chronic diseases, and geroscience aims to target it directly. Established (framework).
- Rapamycin and other interventions extend lifespan in mice. Supported (animal).
- Two years of calorie restriction slightly slowed one DNA-methylation pace-of-aging measure in a human trial. Preliminary.
- No intervention is approved to treat aging, and the TAME trial hasn’t launched. Established (status).
What We Don’t Know
- Whether any intervention slows human aging in a way that delays multiple diseases. Unknown.
- Whether changes in epigenetic clocks translate into better health or longer life. Unknown.
- What the right endpoint for an aging trial is. The proposed TAME design uses a composite of age-related diseases; its sponsor hopes that approach could eventually support an aging indication.
Source Materials
- Kennedy et al., Cell (2014) — Field-defining commentary from geroscience researchers, used for the research framework and healthspan goal. It is a conceptual paper, not evidence that an intervention slows aging in people.
- Waziry et al., Nature Aging (2023) — Secondary analysis of the two-year CALERIE randomized trial in 220 adults without obesity. Calorie restriction produced a small change in DunedinPACE but not PhenoAge or GrimAge; the study measured methylation clocks, not disease incidence, disability or survival. Two authors are DunedinPACE inventors, and the measure has been licensed commercially.
- López-Otín et al., Cell (2023) — Review that expanded the hallmarks-of-aging framework to 12 features and stated its inclusion criteria. This organizes mechanisms; it does not establish that targeting a hallmark improves human clinical outcomes. The paper reports relevant commercial interests, including Life Length, Altos Labs and Rejuveron ties noted in the article.
- Harrison et al., Nature (2009) — National Institute on Aging Interventions Testing Program experiment showing that late-life rapamycin extended lifespan in genetically heterogeneous mice. This is animal evidence and cannot establish human lifespan benefit or safety.
- Barzilai et al., Cell Metabolism (2016) — Perspective proposing the Targeting Aging with Metformin trial. It describes a planned test and rationale, not an initiated trial or efficacy result.
- American Federation for Aging Research — TAME — Sponsor page rechecked September 29, 2026 for the proposed population, duration, sites, fundraising status and regulatory goal. It is an advocacy and fundraising source; no TAME-specific ClinicalTrials.gov registration was located at this review.
- NPR report republished by WUFT (2024) — Journalistic source for Nir Barzilai’s explanation of the generic-drug funding problem and the historical NIA contribution and total-cost estimates. Those figures describe the 2024 funding situation, not a current award or trial launch.
Photo credits
Images from Pexels.
- featured: Photo by Mikhail Nilov — original Pexels photo.
- inline-1: Photo by Tima Miroshnichenko — original Pexels photo.
- inline-2: Photo by Gustavo Fring — original Pexels photo.
Featured image: Image by Great_bru via Envato Elements.
Leave a Reply